BioStem Technologies wins Nasdaq approval, begins trading August 7

What's the deal? BioStem Technologies, a regenerative medicine company that makes perinatal tissue allograft products, said NasdaqDealroom has a profile for this one. Try Dealroom → has approved its common stock for listing on The Nasdaq Capital Market. The stock is expected to begin trading on August 7, 2026, under the ticker "BSEM," moving up from the over-the-counter market.

Why now? Chairman and chief executive officer Jason Matuszewski tied the uplisting to progress "strengthening our foundation, streamlining our operations, and executing on our core business strategy." Shareholders need not take any action, and the ticker stays the same.

What's the endgame? BioStem develops, manufactures, and commercialises allografts derived from perinatal tissue using its proprietary BioRetain, CryoTek, and SteriTek processing technologies. Its portfolio spans the Neox, Clarix, VENDAJE, and American Amnion brands, sold to clinicians across a range of specialties.

Why it matters: Matuszewski said the company expects the move to "expand our access to capital, improve market visibility and liquidity for our shareholders." A Nasdaq listing typically widens the pool of institutional investors that can hold a stock.

The signal: The jump from over-the-counter trading to a national exchange marks a maturation step for BioStem, which holds accreditation from the American Association of Tissue Banks and operates under current Good Tissue Practices and current Good Manufacturing Practices standards. The uplisting positions it to compete for capital and talent in the broader regenerative medicine market.

Read more: AP News

Image credit: pingnews.com